Expression of hepatocyte growth factor activator inhibitor type 1 in human hepatocellular carcinoma and postoperative outcomes

World Journal of Surgery

Volumn 34, Issue 7, 2010, Pages 1563-1571

  Funagayama, Mayumi ^a   Kondo, Kazuhiro ^a   Chijiiwa, Kazuo ^a   Kataoka, Hiroaki ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKOCYTE ELASTASE INHIBITOR; SPINT1 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; DISEASE COURSE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROTEINASE INHIBITORY PROTEINS, SECRETORY; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955473592     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-010-0517-1     Document Type: Article

References (38)

1. World Health Organization. Mortality database. Available at http://www.who.int/whosis/en. Accessed Feb 2009
2. Liver Cancer Study Group of Japan 1990 Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment Ann Surg 211 277 287
3. BI Carr 2004 Hepatocellular carcinoma: current management and future trends Gastroenterology 127 S218 S224 10.1053/j.gastro.2004.09.036 15508087 (Pubitemid 39423390)
4. K Shirabe K Takenaka A Taketomi, et al. 1996 Postoperative hepatitis status as a significant risk factor for recurrence in cirrhotic patients with small hepatocellular carcinoma Cancer 77 1050 1055 10.1002/(SICI)1097- 0142(19960315)77:6<1050::AID-CNCR7>3.0.CO;2-L 1:STN:280: DyaK283jt1Cmtg%3D%3D 8635122 (Pubitemid 26080893)
5. M Aramaki K Kawano T Kai, et al. 1999 Treatment for extrahepatic metastasis of hepatocellular carcinoma following successful hepatic resection Hepatogastroenterology 46 2931 2934 1:STN:280:DC%2BD3c%2FktFOqtg%3D%3D 10576375
6. M Kuang BG Peng MD Lu, et al. 2004 Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma Clin Cancer Res 10 1574 1579 10.1158/1078-0432.CCR-03- 0071 1:CAS:528:DC%2BD2cXhvFClsLY%3D 15014006 (Pubitemid 38435545)
7. WY Lau TW Leung SK Ho, et al. 1999 Adjuvant intra-arterial iodine-131-labelled lipiodol for respectable hepatocellular carcinoma: a prospective randomized trial Lancet 353 797 801 10.1016/S0140-6736(98)06475-7 1:CAS:528:DyaK1MXhvFemsbc%3D 10459961 (Pubitemid 29110405)
8. M Jeffers S Rong GF Van de Woude 1996 Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network Mol Cell Biol 16 1115 1125 1:CAS:528:DyaK28XhtFOls7k%3D 8622656
9. T Kamiyama Y Une J Uchino, et al. 1998 Hepatocyte growth factor enhances the invasion activity of human hepatocellular carcinoma cell lines Int J Oncol 12 655 659 1:CAS:528:DyaK1cXitVSrsL0%3D 9472107
10. A Monvoisin V Neaud V De Lédinghen, et al. 1999 Direct evidence that hepatocyte growth factor-induced invasion of hepatocellular carcinoma cells is mediated by urokinase J Hepatol 30 511 518 10.1016/S0168-8278(99)80113-5 1:CAS:528:DyaK1MXjtVWqsLg%3D 10190737 (Pubitemid 29113243)
11. E Santoni-Rugiu KH Preisegger A Kiss, et al. 1996 Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model Proc Natl Acad Sci USA 93 9577 9582 10.1073/pnas.93.18.9577 1:CAS:528:DyaK28XlsFeitLc%3D 8790372 (Pubitemid 26296650)
12. ML Liu WM Mars GK Michalopoulos 1995 Hepatocyte growth factor inhibits cell proliferation in vivo of rat hepatocellular carcinomas induced by dimethylnitrosamine Carcinogenesis 16 841 843 10.1093/carcin/16.4.841 1:CAS:528:DyaK2MXlsF2isLg%3D 7728965
13. K Suzuki N Hayashi Y Yamada, et al. 1994 Expression of the c-met protooncogene in human hepatocellular carcinoma Hepatology 20 1231 1236 10.1002/hep.1840200520 1:STN:280:DyaK2M%2Fht1Wguw%3D%3D 7927256 (Pubitemid 24323571)
14. A D'Errico M Fiorentino A Ponzetto, et al. 1996 Liver hepatocyte growth factor does not always correlate with hepatocellular proliferation in human liver lesions: its specific receptor c-met does Hepatology 24 60 64 8707284
15. T Ueki J Fujimoto T Suzuki, et al. 1997 Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma Hepatology 25 862 866 10.1002/hep.510250413 1:STN:280:DyaK2s3ltV2jtA%3D%3D 9096589 (Pubitemid 27157127)
16. T Shimomura M Ochiai J Kondo, et al. 1992 A novel protease obtained from FBS-containing culture supernatant, that processes single-chain form hepatocyte growth factor to two chain form in serum-free culture Cytotechnology 8 219 229 10.1007/BF02522039 1:STN:280:DyaK3s%2FgtF2jtA%3D%3D 1368819
17. T Shimomura J Kondo M Ochiai, et al. 1993 Activation of the zymogen of hepatocyte growth factor activator by thrombin J Biol Chem 268 22927 22932 1:CAS:528:DyaK3sXlslKnt7c%3D 8226803
18. T Shimomura K Denda A Kitamura, et al. 1997 Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor J Biol Chem 272 6370 6376 10.1074/jbc.272.10.6370 1:CAS:528:DyaK2sXhvVOlt78%3D 9045658 (Pubitemid 27118113)
19. K Nagata S Hirono A Ido, et al. 2001 Expression of hepatocyte growth factor activator and hepatocyte growth factor activator inhibitor type 1 in human hepatocellular carcinoma Biochem Biophys Res Commun 289 205 211 10.1006/bbrc.2001.5916 1:CAS:528:DC%2BD3MXot12ht7g%3D 11708800 (Pubitemid 33108815)
20. K Kondo K Chijiiwa M Funagayama, et al. 2008 Hepatic resection is justified for elderly patients with hepatocellular carcinoma World J Surg 32 2223 2229 10.1007/s00268-008-9688-4 18642042
21. S Fujiyama T Morishita O Hashiguchi, et al. 1988 Plasma abnormal prothrombin (des-gamma-carboxy prothrombin) as a marker of hepatocellular carcinoma Cancer 61 1621 1628 10.1002/1097-0142(19880415)61:8<1621::AID- CNCR2820610820>3.0.CO;2-C 1:STN:280:DyaL1c7msVOitQ%3D%3D 2450634
22. H Kataoka T Suganuma T Shimomura, et al. 1999 Distribution of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in human tissues: cellular surface localization of HAI-1 in simple columnar epithelium and its modulated expression in injured and regenerative tissues J Histochem Cytochem 47 673 682 1:CAS:528:DyaK1MXjtlKgsrY%3D 10219059
23. RN Pugh IM Murray-Lyon JL Dawson, et al. 1973 Transection of the oesophagus for bleeding oesophageal varices Br J Surg 60 646 649 10.1002/bjs.1800600817 1:STN:280:DyaE3s3jsVWqsw%3D%3D 4541913
24. Liver Cancer Study Group of Japan (2003) General rules for the clinical and pathological study of primary liver cancer, 2nd edn. Kanehara Press, Tokyo
25. RTP Poon ST Fan J Wong 2000 Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma Ann Surg 232 10 24 10.1097/00000658-200007000-00003 (Pubitemid 30456545)
26. K Kondo K Chijiiwa I Makino, et al. 2005 Risk factors for early death after liver resection in patients with solitary hepatocellular carcinoma J Hepatobiliary Pancreat Surg 12 399 404 10.1007/s00534-005-1009-9 16258809 (Pubitemid 41662451)
27. AW Ke GM Shi J Zhou, et al. 2009 Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma Hepatology 49 491 503 10.1002/hep.22639 1:CAS:528:DC%2BD1MXivFWhtrc%3D 19065669
28. H Kataoka S Miyata S Uchinokura, et al. 2003 Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor Cancer Metastasis Rev 22 223 236 10.1023/A:1023051500010 1:CAS:528:DC%2BD3sXis1CjtLw%3D 12784998 (Pubitemid 36561059)
29. WC Tsai YC Chao WH Lee, et al. 2006 Increasing EMMPRIN and matriptase expression in hepatocellular carcinoma: tissue microarray analysis of immunohistochemical scores with clinicopathological parameters Histopathology 49 388 395 10.1111/j.1365-2559.2006.02516.x 16978202 (Pubitemid 44401546)
30. JY Kang M Dolled-Filhart IT Ocal, et al. 2003 Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer Cancer Res 63 1101 1105 1:CAS:528:DC%2BD3sXhs1agtLw%3D 12615728
31. BS Knudsen JM Lucas L Fazli, et al. 2005 Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate Am J Pathol 167 255 266 1:CAS:528:DC%2BD2MXms1eit70%3D 15972969
32. S Miyata S Uchinokura T Fukushima, et al. 2005 Diverse roles of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in the growth of glioblastoma cells in vivo Cancer Lett 227 83 93 10.1016/j.canlet.2005.01.010 1:CAS:528:DC%2BD2MXmvVCgu74%3D 16051034 (Pubitemid 41033095)
33. H Kataoka T Shimomura T Kawaguchi, et al. 2000 Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment J Biol Chem 275 40453 40462 10.1074/jbc.M006412200 1:CAS:528:DC%2BD3MXhsFertA%3D%3D 11013244 (Pubitemid 32064680)
34. H Itoh S Naganuma N Takeda, et al. 2004 Regeneration of injured intestinal mucosa is impaired in hepatocyte growth factor activator-deficient mice Gastroenterology 127 1423 1435 10.1053/j.gastro.2004.08.027 1:CAS:528:DC%2BD2cXhtVKisr3M 15521012 (Pubitemid 39457769)
35. H Itoh H Kataoka 2002 Roles of hepatocyte growth factor activator (HGFA) and its inhibitor HAI-1 in the regeneration of injured gastrointestinal mucosa J Gastroenterol 37 Suppl 14 15 21 12572861
36. MD Oberst LY Chen K Kiyomiya, et al. 2005 HAI-1 regulates activation and expression of matriptase, a membrane-bound serine protease Am J Physiol Cell Physiol 289 C462 C470 10.1152/ajpcell.00076.2005 1:CAS:528:DC%2BD2MXotFajtr4%3D 15800053 (Pubitemid 41008893)
37. D Kirchhofer M Peek MT Lipari, et al. 2005 Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2 FEBS Lett 579 1945 1950 10.1016/j.febslet.2005.01.085 1:CAS:528:DC%2BD2MXisFGqu7g%3D 15792801 (Pubitemid 40404036)
38. CH Chen KY Su MH Tao, et al. 2006 Decreased expressions of hepsin in human hepatocellular carcinomas Liver Int 26 774 780 10.1111/j.1478-3231.2006. 01307.x 16911458 (Pubitemid 44165244)